Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis

BACKGROUND: Postoperative docetaxel plus S-1 (DS) chemotherapy is expected to be the standard therapeutic strategy for pStage III gastric cancer based on the results of the JACCRO GC-07 study. Neoadjuvant chemotherapy (NAC) is thought to have several advantages over adjuvant settings. OBJECTIVE: Thi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Surg Oncol
Main Authors: Kano, Masayuki, Hayano, Koichi, Hayashi, Hideki, Hanari, Naoyuki, Gunji, Hisashi, Toyozumi, Takeshi, Murakami, Kentaro, Uesato, Masaya, Ota, Satoshi, Matsubara, Hisahiro
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2019
Assuntos:
Gastrointestinal Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510880/
https://ncbi.nlm.nih.gov/pubmed/30977014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-07299-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares